Dr. Anthony Chilton obtained an honors degree in Chemistry from the University of East Anglia (1981). He continued his studies at the University of Hertfordshire, completing a PhD in Analytical Chemistry from (1993). As founder of C2CK Consulting Inc., Dr. Chilton continues to advise on strategic planning and implementation for organizational growth and development while mentoring companies to meet financial and operational targets. His projects typically include bioanalytical method development and problem solving, support of both clinical and non-clinical projects in a vast array of therapeutic areas and GLP audits of service providers.
Dr. Chilton is a consultant for Radyus Research and brings with him over 20 years of experience in senior leadership roles in biotech, large pharma, contract research organizations, and the pharmaceutical industry. As a senior level executive, he has experience with leadership and management gained in the international life sciences industry with pharmaceutical and contract service organizations. He is a creative, results-oriented professional with proven ability to build businesses and grow both organizations and staff, and has experience developing business strategy, implementing organizational change and harmonizing cross functional teams in multi-site organizations, improving operational effectiveness.
Chilton’s executive roles in the pharmaceutical and consulting space as the Vice President of Cardinal Health, the Senior Director DM/PK at Atherogenics, CEO and COO of BASi Inc., Senior Director at Roivant Sciences, Founder of C2K2 Consulting, Consultant at Big Data Solutions, and Chief Strategy Officer for NTxBio are invaluable to our work at Radyus.
He has long-standing experience working in drug discovery, preclinical and early clinical phase development, gaining operational and regulatory experience in Canada, US and Europe. As the President/CEO of a midsize public traded multinational CRO, he also led a successful reorganization and expansion of the company. As a consultant, Tony has worked on a variety of drug development programs, including programs for Cystic Fibrosis, pediatric renal disease, atherosclerosis, and diabetes.
Dr. Chilton obtained his honors degree in Chemistry from the University of East Anglia and his PhD in Analytical Chemistry from the University of Hertfordshire.
Chilton has acquired in depth knowledge and experience in a range of therapeutic areas with interest in ADME/PK, bioanalytical, preclinical development. He co-developed a novel sterile formulation to support oncology clinical trials, giving him practical experience in drug discovery and development process.
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
I am devoted to working with new companies to realize new approaches and technologies to discover better cost-effective drugs to reach all patients in need.
